- Home
- MYSE vs BIVI Comparison
MYSE vs BIVI Comparison
Compare MYSE & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYSE | BIVI |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | 11 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4M | 10.3M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | MYSE | BIVI |
|---|---|---|
| Price | $2.53 | $1.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 101.2K | ★ 542.6K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.31 | $0.82 |
| 52 Week High | $5.77 | $2.31 |
Technical Indicators
Market Signals| Indicator | MYSE | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 52.13 | 43.60 |
| Support Level | $2.24 | $1.23 |
| Resistance Level | $2.83 | $1.51 |
| Average True Range (ATR) | 0.16 | 0.20 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 47.06 | 42.52 |
Price Performance
Historical ComparisonAbout MYSE Myseum Inc.
Myseum.AI Inc is an integrate proprietary privacy-first artificial intelligence (AI) and social media technology company. The Company is developing privacy-first agentic localized AI agents to assist in managing personal media such as photos, videos and messages, while maintaining privacy.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.